Chugai Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4519.T

Chugai Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2023: 39.93%

Chugai Pharmaceutical Co., Ltd. EBT Margin is 39.93% for the year ending December 31, 2023, a -5.27% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Chugai Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2022 was 42.16%, a 0.50% change year over year.
Chugai Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2021 was 41.95%, a 10.71% change year over year.
Chugai Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2020 was 37.89%, a 25.07% change year over year.
Chugai Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2019 was 30.30%, a 44.64% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Tokyo Stock Exchange: 4519.T

Chugai Pharmaceutical Co., Ltd.

CEO	Dr. Osamu Okuda
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	Nihonbashi Mitsui Tower
Employees	7,604
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Key trends

Past 5 years